Onconic Therapeutics
476060.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$579.37B
Close$
Share Statistics
| Market cap | $579.37 Billion |
|---|---|
| Enterprise Value | $521.48 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $358.67 |
| Beta | 0.19 |
| Outstanding Shares | 45,334,362 |
Return
| Return on Equity | 28.27% |
|---|---|
| Return on Assets | 26.08% |
| Return on Invested Capital | 21.42% |
Valuation & Multiples
| P/E Ratio | 27.36 |
|---|---|
| PEG | -1.09 |
| Price to Sales | 7.05 |
| Price to Book Ratio | 6.75 |
| Enterprise Value to Revenue | 6.35 |
| Enterprise Value to EBIT | 28.35 |
| Enterprise Value to Net Income | 21 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$21.20 B
Average shareholder expectationNext Earnings Call
Expected Date
November 17, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$24.60 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Onconic Therapeutics
38 employees
CEO: John Kim Onconic Therapeutics, Inc. operates as a biopharmaceutical enterprise, primarily dedicated to the discovery and advancement of novel therapeutic solutions. Its research and development initiatives principally focus on creating new medica...